Background: It is not clear if the administration of iodine-131 in patients with differentiated thyroid cancers induces relevant cystitis and lower urinary tract infections (UTIs). The aim of this study was to evaluate the impact of oral administration of hyaluronic acid and chondroitin sulphate (HA&CS) on the frequency of UTIs induced by iodine-131. Methods: In this study, 166 female patients with a surgical diagnosis of differentiated thyroid cancer who were hospitalized in Sant ’Andrea Hospital of Rome to undergo the first cycle of therapy with iodine-131 for thyroid remnant ablation were evaluated. Sixty-one patients were treated with HA&CS for 8 days, and thirty-nine patients were treated with HA&CS for 17 days. Sixty-six patients were not treated with HA&CS and were used as control subjects. Patients underwent urinalysis at different time points: immediately before131I therapy, two days later, and one week later. Patients were divided in six groups based on whether they received the treatment with HA&CS, its duration, and whether they developed a UTI: group A,n= 51 patients who did not receive HA&CS and did not develop UTI; group B1,n= 37 patients treated with HA&CS for 8 days and did not develop UTI; group B2,n= 29 patients treated with HA&CS for 17 days and did not develop UTI; group C,n= 15 patients who did not receive HA&CS and developed UTI; group D1,n= 24 patients treated with HA&CS for 8 days and developed UTI; group D2,n= 10 patients treated with HA&CS for 17 days and developed UTI. Results: The bacteria count, red blood cells and white blood cells did not change when group A was compared to both group B1 and group B2, while pH and epithelial cells showed a decrease over time when comparing group A and group B2 (p= 0.01 andp< 0.0001, respectively). Comparing group C with group D1 and group D2, patients who did not receive HA&CS (group C) showed a higher bacteria and epithelial cell count compared to those who were pre-treated with HA&CS. Conclusions: HA&CS could be an effective supportive therapy to prevent and mitigate UTIs in patients treated with131I.
背景：目前尚不清楚分化型甲状腺癌患者接受碘-131治疗后是否会诱发相关性膀胱炎及下尿路感染。本研究旨在评估口服透明质酸与硫酸软骨素对碘-131所致尿路感染发生率的影响。方法：本研究纳入166例经手术确诊为分化型甲状腺癌的女性患者，均于罗马圣安德烈医院住院接受首次碘-131甲状腺残余组织清除治疗。其中61例患者接受为期8天的HA&CS治疗，39例患者接受为期17天的HA&CS治疗，66例未接受HA&CS治疗的患者作为对照组。所有患者分别于碘-131治疗前、治疗后2天及治疗后1周进行尿液检测。根据是否接受HA&CS治疗、治疗时长及是否发生尿路感染将患者分为六组：A组（n=51）未接受HA&CS治疗且未发生尿路感染；B1组（n=37）接受8天HA&CS治疗且未发生尿路感染；B2组（n=29）接受17天HA&CS治疗且未发生尿路感染；C组（n=15）未接受HA&CS治疗但发生尿路感染；D1组（n=24）接受8天HA&CS治疗但发生尿路感染；D2组（n=10）接受17天HA&CS治疗但发生尿路感染。结果：A组与B1组、B2组比较时，细菌计数、红细胞及白细胞数量均无显著变化；而A组与B2组比较时，pH值及上皮细胞数量随时间推移呈下降趋势（p值分别为0.01和<0.0001）。C组与D1组、D2组比较显示，未接受HA&CS治疗的C组患者较接受HA&CS预处理的患者具有更高的细菌及上皮细胞计数。结论：HA&CS可能成为预防和减轻碘-131治疗患者尿路感染的有效辅助疗法。
肿瘤(癌症)患者之家